“Hidden Trials” In The Age Of Transparency: ClinicalTrials.gov Director Sees Room For Improvement
This article was originally published in RPM Report
The global push towards clinical trial registration and transparency hasn’t ended the problem of “hidden trials,” the head of NIH’s ClinicalTrials.gov cautions. But the existence of registries helps better analyze the problem and offers some fairly simple steps to get closer to the goal of assuring that all clinical trials are available to the public.
You may also be interested in...
The National Institutes of Health is still drafting regulations, but Rep. Markey’s TEST Act, which would impose more extensive reporting requirements, has won praise from stakeholders for some of its definitional details. In an election season, its prospects for passing are slim, but aspects of the legislation could serve as a model for pending regulations.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.